CRDL: SEC Form 6-K filed by Cardiol Therapeutics Inc.
Cardiol files $75M at-the-market share sale program via Jefferies, dilutive to existing holders, dated Nov 3, 2026.
What this filing says
Cardiol Therapeutics has agreed with Jefferies LLC that it may sell up to US$75,000,000 of its common shares over time through an at-the-market program. Shares would be sold only when the company issues placement notices, so the amount actually raised and the timing are not yet known. For a current shareholder, this means possible dilution as new shares are issued, though the filing does not state how many shares would be sold.
Key figures
- Maximum program amount
- US$75,000,000
- Agreement date
- November 3, 2026
Positive for shareholders
- The program gives the company a flexible way to raise capital on demand.
Negative for shareholders
- New common shares issued under the program could dilute existing shareholders' ownership.
- Sales depend on placement notices the company chooses to deliver, so proceeds are uncertain.
Written by Quantisnow AI from this filing. Not financial advice.
Form 6-K main document
Key terms
- Open market sale agreement:
- A contract allowing a company to sell new shares gradually through a broker at prevailing market prices.
- Placement notice:
- A formal request from the company to its sales agent to issue a specified batch of shares.
- Shelf registration:
- A pre-approved registration that lets a company sell securities over time without a new offering each time.
FAQ
How much can Cardiol Therapeutics raise under this agreement?
The agreement allows Cardiol Therapeutics to sell common shares with an aggregate offering price of up to US$75,000,000 through Jefferies LLC.
How will the shares be sold?
The company may sell shares through Jefferies acting as sales agent, or directly to Jefferies acting as principal, based on placement notices the company delivers over the agreement's term.
Historical context for CRDL
Across the 25 sessions after earlier CRDL headlines, the stock closed higher 15 times and lower 9 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CRDL | SPY |
|---|---|---|---|
| Nov 4, 2026 | Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC | -3.8% | +1.7% |
| Sep 23, 2026 | Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy | -6.3% | -0.7% |
| Sep 16, 2026 | Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds | +2.7% | -0.4% |
| Sep 11, 2026 | Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission | +0.8% | +0.9% |
| Sep 9, 2026 | Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference | +2.9% | -0.5% |
| Aug 26, 2026 | B. Riley Securities initiated coverage on Cardiol Therapeutics with a new price target | +7.0% | +0.0% |
Keep researching CRDL
- What is Form 6-K?The SEC form foreign private issuers use to furnish material information they publish at home, such as earnings releases and major announcements.
- Form 8-K explainedWhat a Form 8-K is, when it is due, and what each key item number means, from 1.01 material agreements and 2.02 earnings to 4.02 restatements and 5.02 executive changes.
- CRDL financial statementsRevenue, profit, cash flow and balance sheet from Cardiol Therapeutics Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Follow CRDL and get a push notification the moment its next story breaks.